Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + AMG 176 in R/R Hematologic Malignancies
NCT03797261Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of Tapotoclax in acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL), sponsored by AbbVie Inc. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 28 days and Number of Participants With Adverse Events up to 4 years. Started Mar 2019; status: terminated.
02
Drugs
Tapotoclax
03
Conditions
acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03797261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03797261.